BSE · 544611
Mahamaya Lifesciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹267 Cr with net profit ₹13 Cr — a 4.84% net margin, versus 3.2% the period before.
Shareholding
As of 2026-03-31
- Promoter56.35%
- Public36.36%
- FII4.77%
- DII2.52%
584 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.85× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pesticides / Agrochemicals - Indian · ranked #21 of 29 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| UPL Limited | ₹51,406 Cr | 28.8 | 1.48 | 5.54% | 3.71% |
| PI Industries Ltd. | ₹41,782 Cr | 208.63 | 3.73 | 11.76% | 0.2% |
| Sumitomo Chemical India Ltd. | ₹25,042 Cr | 43.82 | 7.39 | 16.02% | 17.86% |
| Sharda Cropchem Ltd. | ₹7,440 Cr | 23.35 | 2.37 | 21.71% | 12.93% |
| Dhanuka Agritech Ltd. | ₹4,589 Cr | 46.93 | 2.73 | 21.17% | 14.59% |
| NACL Industries Limited | ₹4,571 Cr | — | 6.69 | 2.49% | 0.29% |
| Rallis India Ltd. | ₹3,789 Cr | 28.19 | 2.03 | 9.99% | 6.31% |
| Bhagiradha Chemicals & Industries Ltd. | ₹3,463 Cr | 861.45 | 4.96 | 2.6% | 3.39% |
| Bharat Rasayan Ltd. | ₹2,121 Cr | 55.59 | 1.66 | 11.43% | 11.73% |
| Insecticides India Ltd. | ₹1,831 Cr | 156.5 | 1.5 | 0.11% | 6.51% |
| Mahamaya Lifesciences Limited(this company) | ₹393 Cr | 23.8 | 3.22 | 13.55% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashMahamaya Lifesciences Limited is listed with a market capitalization of Rs 402 Cr. The company reported a revenue of Rs 267.17 Cr and an EPS of Rs 7.06. The return on equity (ROE) stands at 13.55% and return on capital employed (ROCE) at 15.05%.
Positives
- +Revenue grew from Rs 90.16 Cr in Mar 2022 to Rs 267.17 Cr in Mar 2025.
- +Net profit increased from Rs 2.72 Cr in Mar 2022 to Rs 12.94 Cr in Mar 2025.
- +Promoter holding is 56.35% as of Mar 31, 2026.
- +ROE is 13.55% and ROCE is 15.05%.
Negatives
- −The debt-to-equity ratio of 1.52 indicates a relatively high level of debt.
- −Promoter holding decreased from 77.27% in Feb 2025 to 56.35% in Mar 2026.
- −Quarterly results are not disclosed in the provided data.
- −The profit margin is 4.85% for the latest annual period.
Financial Performance
Mahamaya Lifesciences Limited reported revenue of Rs 267.17 Cr for the fiscal year ending March 2025. This marks an increase from Rs 162.83 Cr in March 2024. Net profit grew to Rs 12.94 Cr in March 2025 from Rs 5.22 Cr in March 2024. The company's EPS was Rs 7.60 for March 2025, compared to Rs 41.79 in March 2024.
Profitability & Returns
The company’s return on equity (ROE) is 13.55% and the return on capital employed (ROCE) is 15.05%. The calculated profit margin for the latest annual period is 4.85%. EBITDA for March 2025 was Rs 24.19 Cr.
Balance Sheet
Mahamaya Lifesciences Limited has a debt-to-equity ratio of 1.52. The book value per share is Rs 52.09. The company has not provided any dividend yield data.
Ownership & Pledges
As of March 31, 2026, promoters held 56.35% of the company's shares. Public shareholding was 36.36%, while DIIs held 2.52% and FIIs held 4.77%. There were no promoter pledges reported for the latest period.
Regulatory & Surveillance
No specific regulatory or surveillance measures have been reported for Mahamaya Lifesciences Limited in the provided data. The company has 584 shareholders as of March 31, 2026.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Mahamaya Lifesciences Limitedshare price & fundamentals